US nonprofit GRID Alternatives launches new projects to provide renewable energy
As part of Illumina’s long-term commitment to sustainability, the Illumina Corporate Foundation made a one-year, $500,000 grant to support GRID Alternatives (Generating Renewable Ideas and Development Alternatives), a nonprofit committed to increasing access to renewable energy and training people for clean energy jobs.
Full agenda now available for September 28–October 1 event
SAN DIEGO, September 12, 2022 /3BL Media/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced the release of the full agenda for its inaugural Illumina Genomics Forum. The agenda for the four-day event can be seen here.
Presentations will include evidence on how genomic signatures and next-generation sequencing can improve the care of patients with cancer
SAN DIEGO, September 7, 2022 / 3BL Media / — Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced the upcoming presentation of multiple oncology research abstracts at this year’s European Society of Medical Oncology (ESMO) annual meeting, September 9–13 in Paris. The abstracts underscore the value of next-generation sequencing (NGS) and Illumina’s oncology assays for cancer research and patient care.
Global conference to focus on advancing the life-saving impacts of genomic health care
SAN DIEGO, September 2, 2022 /3BL Media/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will feature International Tennis Hall of Fame member Chris Evert as a special guest at its inaugural Illumina Genomics Forum (IGF) on October 1. Evert, who was diagnosed with stage 1C ovarian cancer earlier this year, will participate in a fireside chat discussing how genomics can improve early cancer detection, lead to more proactive, effective treatment of cancer, and help save lives.
Canada’s STREAM project uses genomics to advance watershed health monitoring
Rivers and streams are vital to communities everywhere, for drinking water, transportation, and leisure. But pollution, drought, and climate change are taking their toll, making watershed monitoring more important every year. That’s the urgency driving the recent Illumina philanthropic grantee Sequencing the Rivers for Environmental Assessment and Monitoring (STREAM), which samples freshwater rivers throughout Canada.
New partnership will use the power of high-throughput sequencing to measure and understand marine life in our oceans at a rate that eclipses traditional research methods
SAN DIEGO, August. 17, 2022 /3BL Media/ -- Minderoo Foundation and Illumina, Inc. (NASDAQ: ILMN), today announced a 40 million Australian dollar (US $27.8 million) partnership that will leverage the power of genomics to accelerate scientific understanding of marine systems and help marine conservationists make informed decisions. The three-year partnership demonstrates a shared commitment to conserving marine biodiversity and understanding the changing marine ecosystems on which people and national economies depend.
Session will showcase the rapidly growing use and groundbreaking impact of clinical genomics in oncology
SAN DIEGO, August 24, 2022 /3BL Media/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced that it will feature Dr. Karen Knudsen, CEO of the American Cancer Society, at its inaugural Illumina Genomics Forum (IGF) on October 1. Dr. Knudsen will participate in an on-stage conversation with Dr. Phil Febbo, Illumina's Chief Medical Officer, about the landscape of cancer treatment and research, including what is currently being done to support the prevention, detection, and treatment of cancer.
The innovation in next-generation sequencing (NGS) technologies and relentless efforts to combat COVID-19 worldwide contributed to Illumina’s inclusion. In 2022, China CDC used the Illumina sequencing platform to report the first imported case confirmed to be infected with the Omicron variant of COVID-19.